PNR-33. MOLECULAR RE-EVALUATION OF INSTITUTIONALLY DIAGNOSED CNS-PNETS: CLINICAL CONSEQUENCES OF CONFINED DIAGNOSTIC GROUPS
Katja von Hoff1, Jordan R. Hansford23, Giles Robinson1, Eugene Hwang6, Sarah Lear8, Barry Pizer8, Dannus G. van Vuuren7, Christelle Dufour10, James Olson7, Nicholas G. Gottardo32, and Marcel Kool26; 1University Medical Hospital for Children and The University of Western Australia, Perth, Australia; 2Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 3University of California, Los Angeles, CA, USA; 4Nationwide Children’s Hospital and the Ohio State University College of Medicine, Columbus, OH, USA; 5University of Münster, Muenster, Germany; 6Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; 7Department of Pediatric Hematology and Oncology, University Hospital, Heidelberg, Germany; 8Northern Institute for Cancer Research, Newcastle upon Tyne, Italy; 9Neuropathology, University La Sapienza, and IRCCS Neurontom Pozzilli, Isernia, Rome, Italy; 10Institute of Neurology, Medical University of Vienna, Vienna, Austria; 11Department of Neuropathology, University of Bonn, Bonn, Germany; 12Princess Margaret Hospital for Children and The University of Western Australia, Perth, Australia

Abstracts

Consequences of Confined Diagnostic Groups

In order to develop appropriate treatment strategies for these new molecular entities, it is essential to know the clinical response and outcome from previously applied treatment strategies. Conversely, it is valuable to analyze the outcome of patients with tumors treated as per CNS-PNET strategies that were reclassified into other known entities. Interestingly, after identifying these new entities, additional cases aligning with these profiles were found among patients with historic diagnoses other than CNS-PNETs. In order to develop appropriate treatment strategies for these new molecular entities, it is essential to know the clinical response and outcome from previously applied treatment strategies. Within a broad international collaborative approach, clinical, molecular and histopathological data are collected for patients with historic diagnoses of CNS-PNET or with tumors not diagnosed as CNS-PNET but that fit the molecular profile of one of the newly defined molecular entities. Clinical and outcome data will be presented for patients with matched molecular profiles.